Axogen (AXGN) vs Medtronic (MDT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Axogen (AXGN) has outperformed Medtronic (MDT) over the past year, gaining 110.8% versus a loss of 10.3%. Over five years, AXGN leads with a +165.6% price change compared with -31.3% for MDT. Medtronic is the larger company by market cap ($112.24 billion vs $2.12 billion), about 52.9 times the size.
On valuation, Medtronic trades at a lower forward P/E (13.7x vs 52.6x for Axogen). Medtronic pays a dividend yielding 3.25%, while Axogen does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AXGN | MDT |
|---|---|---|
| Share price | $36.18 | $87.75 |
| Market cap | $2.12B | $112.24B |
| 1-day change | +0.39% | +2.62% |
| YTD return | +10.54% | -8.65% |
| 1-year return | +110.84% | -10.34% |
| 5-year return | +165.64% | -31.31% |
| P/E ratio (TTM) | — | 21.56 |
| Forward P/E | 52.59 | 13.68 |
| EPS (TTM) | $-0.67 | $4.07 |
| Dividend yield | 0.00% | 3.25% |
| Annual dividend | $0.00 | $2.85 |
| Revenue (latest FY) | — | $36.36B |
| Revenue growth (YoY) | — | +8.43% |
| Net income (latest FY) | — | $4.80B |
| Gross margin | — | 65.02% |
| Operating margin | — | 17.78% |
| Net margin | — | 13.20% |
| 52-week high | $52.91 | $106.33 |
| 52-week low | $15.27 | $73.31 |
| Distance from 52-week high | -31.62% | -17.47% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +48.76% | +19.02% |
| Average volume | 1.22M | 11.49M |
| Shares outstanding | 58.67M | 1.28B |
| Employees | 622 | 95,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Medtronic is about 52.9 times larger than Axogen by market value ($112.24B vs $2.12B).
- AXGN has outperformed MDT by 121.2 percentage points over the past year.
- Medtronic offers a meaningfully higher dividend yield (3.25% vs 0.00%).
About Axogen
AXGN stock →Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 622 employees
About Medtronic
MDT stock →Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 95,000 employees
AXGN vs MDT FAQ
Which is bigger, Axogen or Medtronic?
Medtronic (MDT) is larger, with a market capitalization of $112.24B compared with $2.12B for Axogen (AXGN).
Which stock has performed better over the past year, AXGN or MDT?
AXGN returned +110.84% over the past 12 months, compared with -10.34% for MDT (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Axogen or Medtronic?
Medtronic pays a dividend yielding 3.25%, while Axogen does not currently pay a regular dividend.
Are Axogen and Medtronic in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.